Ovarian Hyperstimulation Syndrome (OHSS) is a potentially serious complication of assisted reproductive technology (ART). It is caused by an exaggerated response to the hormones used to stimulate ovulation during fertility treatments. OHSS can cause a wide range of symptoms, including abdominal pain, nausea, vomiting, and rapid weight gain. In severe cases, OHSS can lead to serious complications, including dehydration, thromboembolism, and even death. As such, it is important for doctors to be aware of the risk factors for OHSS, as well as strategies for prevention and management. This article provides an overview of OHSS, including risk factors, prevention strategies, and management options.
OHSS is a condition that occurs when the ovaries become overly stimulated in response to fertility medications. The ovaries become enlarged and produce an excessive amount of fluid, which can cause abdominal pain and distention. In some cases, the fluid can accumulate in the chest or abdomen, leading to further symptoms such as shortness of breath, nausea, and vomiting. OHSS can range from mild to severe, with the most severe cases requiring hospitalization.
There are several risk factors for OHSS. The most important factor is the type of fertility medication used. Medications that contain human chorionic gonadotropin (hCG) are more likely to cause OHSS than other types of fertility medications. Additionally, certain patient characteristics can increase the risk of OHSS, including age, body mass index (BMI), and ovarian reserve. Women with a higher BMI or lower ovarian reserve are more likely to experience OHSS.
There are several strategies that doctors can use to reduce the risk of OHSS. First, it is important to identify patients at high risk of OHSS before treatment begins. This can be done by assessing patient characteristics such as age, BMI, and ovarian reserve. Second, lower doses of hCG can be used for patients at high risk of OHSS. Third, doctors can use other fertility medications, such as clomiphene citrate, instead of hCG. Finally, doctors can use monitoring techniques such as ultrasound and blood tests to monitor the response to fertility medications and adjust the dose accordingly.
If OHSS does occur, it is important to take measures to manage the condition. Mild cases of OHSS can usually be managed at home with bed rest, fluids, and pain medication. In more severe cases, hospitalization may be necessary. In the hospital, patients may receive intravenous (IV) fluids, diuretics, and blood transfusions. In addition, doctors may recommend canceling the cycle of fertility treatment or freezing any embryos for transfer at a later date.
OHSS is a potentially serious complication of fertility treatments. as well as strategies for prevention and management. By taking steps to identify patients at high risk of OHSS and using appropriate monitoring techniques, doctors can reduce the risk of OHSS and ensure that appropriate management strategies are in place if the condition does occur.
1.
Electronic Sepsis Alerts; Reducing Plaques in Coronary Arteries
2.
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC
3.
Hereditary cancer has a rare and underreported cause.
4.
New imaging guidelines for head and neck cancers, a step toward practice change
5.
BMTs that are "half-matched" are effective in treating severe sickle cell disease.
1.
Oncolytic Adenoviruses Targeting PD-L1: Advancing Cancer Immunotherapy and Tumor Control
2.
Personalized Cancer Vaccines: The Next Frontier in Precision Oncology
3.
Essential Updates in Hematology in Daily Practice
4.
The Predictive Power of Theranostics in Palliative Neuroendocrine Tumor Management
5.
Importance of Early Detection in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
3.
Current Scenario of Cancer- The Incidence of Cancer in Men
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
5.
A New Era in Managing Cancer-Associated Thrombosis
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation